Departmant of Gastroenterology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
Departmant of Gastroenterology, Ümraniye Teaching and Research Hospital, University of Health Sciences, İstanbul, Turkey.
Turk J Gastroenterol. 2022 Jul;33(7):587-595. doi: 10.5152/tjg.2022.21051.
The effect of hepatic steatosis on the response to antiviral therapy administered in chronic hepatitis B patients is yet to be clarified. In this study, our aim was to determine the effect of hepatic steatosis on the virological response in chronic hepatitis B patients who were treated with entecavir or tenofovir disoproxil fumarate.
This retrospective cohort study was performed using the data of liver biopsy-proven chronic hepatitis B patients with or without hepatic steatosis, who received entecavir or tenofovir disoproxil fumarate treatment between 2012 and 2017. The undetectable serum hepatitis B virus deoxyribonucleic acid level under treatment was defined as the complete virological response. The predictors of virological response were determined, and it was checked whether the virological response was affected by hepatic steatosis in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment.
A total of 324 chronic hepatitis B patients, of which 203 (63%) were males, were included in the study. The median age of the patients was 42 years (range: 35-51 years). Hepatic steatosis was observed in 25% of the patients, and steatohepatitis in 4%. The median time to complete virological response was found to be 6 months (range: 3-9 months). In the full analysis model, the log hepatitis B virus deoxyribonucleic acid was determined as the factor most associated with virological response (P < .001). No statistically signifi- cant relationship was detected between hepatic steatosis and virological response (P = .409).
Concomitant hepatic steatosis has no significant impact on the virological response in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment.
肝脂肪变对慢性乙型肝炎患者抗病毒治疗应答的影响尚不清楚。本研究旨在确定脂肪变对接受恩替卡韦或替诺福韦酯治疗的慢性乙型肝炎患者病毒学应答的影响。
本回顾性队列研究使用了 2012 年至 2017 年间接受恩替卡韦或替诺福韦酯治疗的肝活检证实的慢性乙型肝炎患者的资料，这些患者有或无肝脂肪变。治疗下血清乙型肝炎病毒脱氧核糖核酸不可检测定义为完全病毒学应答。确定病毒学应答的预测因素，并检查在接受恩替卡韦或替诺福韦酯治疗的慢性乙型肝炎患者中，脂肪变是否影响病毒学应答。
共纳入 324 例慢性乙型肝炎患者，其中 203 例（63%）为男性，中位年龄为 42 岁（范围：35-51 岁）。25%的患者存在肝脂肪变，4%存在脂肪性肝炎。完全病毒学应答的中位时间为 6 个月（范围：3-9 个月）。在全分析模型中，log 乙型肝炎病毒脱氧核糖核酸被确定为与病毒学应答最相关的因素（P<0.001）。脂肪变与病毒学应答之间未检测到统计学显著关系（P=0.409）。
在接受恩替卡韦或替诺福韦酯治疗的慢性乙型肝炎患者中，合并肝脂肪变对病毒学应答无显著影响。
